325 related articles for article (PubMed ID: 29966261)
1. Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.
Li Q; Guo Z
Molecules; 2018 Jun; 23(7):. PubMed ID: 29966261
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers.
Zhou Z; Mondal M; Liao G; Guo Z
Org Biomol Chem; 2014 May; 12(20):3238-45. PubMed ID: 24728423
[TBL] [Abstract][Full Text] [Related]
3. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
Xu Z; Moyle PM
Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in self-adjuvanting glycoconjugate vaccines.
Manabe Y; Chang TC; Fukase K
Drug Discov Today Technol; 2020 Dec; 37():61-71. PubMed ID: 34895656
[TBL] [Abstract][Full Text] [Related]
5. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines.
Fujita Y; Taguchi H
Ther Deliv; 2012 Jun; 3(6):749-60. PubMed ID: 22838070
[TBL] [Abstract][Full Text] [Related]
6. Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy.
Gupta N; Vedi S; Kunimoto DY; Agrawal B; Kumar R
Vaccine; 2016 Nov; 34(46):5677-5688. PubMed ID: 27693020
[TBL] [Abstract][Full Text] [Related]
7. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
[TBL] [Abstract][Full Text] [Related]
8. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand.
Abdel-Aal AB; El-Naggar D; Zaman M; Batzloff M; Toth I
J Med Chem; 2012 Aug; 55(15):6968-74. PubMed ID: 22800462
[TBL] [Abstract][Full Text] [Related]
9. Synthetic vaccines: the role of adjuvants in immune targeting.
Jiang ZH; Koganty RR
Curr Med Chem; 2003 Aug; 10(15):1423-39. PubMed ID: 12871139
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate-monophosphoryl lipid a conjugates are fully synthetic self-adjuvanting cancer vaccines eliciting robust immune responses in the mouse.
Wang Q; Zhou Z; Tang S; Guo Z
ACS Chem Biol; 2012 Jan; 7(1):235-40. PubMed ID: 22013921
[TBL] [Abstract][Full Text] [Related]
11. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.
Gavin AL; Hoebe K; Duong B; Ota T; Martin C; Beutler B; Nemazee D
Science; 2006 Dec; 314(5807):1936-8. PubMed ID: 17185603
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Immunological Comparison of Differently Linked Lipoarabinomannan Oligosaccharide-Monophosphoryl Lipid A Conjugates as Antituberculosis Vaccines.
Wang L; Feng S; Wang S; Li H; Guo Z; Gu G
J Org Chem; 2017 Dec; 82(23):12085-12096. PubMed ID: 29112822
[TBL] [Abstract][Full Text] [Related]
14. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines.
Chua BY; Zeng W; Jackson DC
Methods Mol Biol; 2008; 494():247-61. PubMed ID: 18726578
[TBL] [Abstract][Full Text] [Related]
16. Use of defined TLR ligands as adjuvants within human vaccines.
Duthie MS; Windish HP; Fox CB; Reed SG
Immunol Rev; 2011 Jan; 239(1):178-96. PubMed ID: 21198672
[TBL] [Abstract][Full Text] [Related]
17. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
Kumar S; Sunagar R; Gosselin E
Front Immunol; 2019; 10():1144. PubMed ID: 31191528
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration.
Patil HP; Murugappan S; de Vries-Idema J; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
Eur J Pharm Biopharm; 2015 Jun; 93():231-41. PubMed ID: 25896446
[TBL] [Abstract][Full Text] [Related]
19. Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.
Gupta S; Termini JM; Kanagavelu S; Stone GW
Immunol Res; 2013 Dec; 57(1-3):303-10. PubMed ID: 24198065
[TBL] [Abstract][Full Text] [Related]
20. Protein Carriers for Glycoconjugate Vaccines: History, Selection Criteria, Characterization and New Trends.
Micoli F; Adamo R; Costantino P
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
